Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 9, Issue 7, Pages e002851
Publisher
BMJ
Online
2021-07-30
DOI
10.1136/jitc-2021-002851
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
- (2021) Robert Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Baseline modified Glasgow prognostic score associated with survival in metastatic urothelial cell carcinoma treated with immune checkpoint inhibitors
- (2021) Jacqueline T. Brown et al. ONCOLOGIST
- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Resistance to Checkpoint Inhibition in Cancer Immunotherapy
- (2020) Luisa Barrueto et al. Translational Oncology
- Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors
- (2020) Julie M. Shabto et al. Cancer Medicine
- Dynamic Evaluation of the Modified Glasgow Prognostic Scale in Patients With Resected, Localized Clear Cell Renal Cell Carcinoma
- (2020) Dattatraya Patil et al. UROLOGY
- The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses
- (2020) Alireza Labani-Motlagh et al. Frontiers in Immunology
- 696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial
- (2020) T.K. Choueiri et al. ANNALS OF ONCOLOGY
- Discrepancies between genitourinary cancer patients' and clinicians' characterization of the Eastern Cooperative Oncology Group performance status
- (2020) Cristiane Decat Bergerot et al. CANCER
- The tumor microenvironment
- (2020) Nicole M. Anderson et al. CURRENT BIOLOGY
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Post-treatment Glasgow Prognostic Score Predicts Efficacy in Advanced Non-small-cell Lung Cancer Treated With Anti-PD1
- (2019) NORIMITSU KASAHARA et al. ANTICANCER RESEARCH
- Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy
- (2019) Mehmet Asim Bilen et al. ONCOLOGIST
- Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
- (2019) Dylan J. Martini et al. ONCOLOGIST
- Mechanisms of resistance to immune checkpoint inhibitors
- (2018) Russell W Jenkins et al. BRITISH JOURNAL OF CANCER
- Mechanisms of Resistance to PD-1 and PD-L1 Blockade
- (2018) Theodore S. Nowicki et al. CANCER JOURNAL
- Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab
- (2018) Mehmet Asim Bilen et al. Clinical Genitourinary Cancer
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
- (2018) David F. McDermott et al. NATURE MEDICINE
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- The modified glasgow prognostic score is an independent prognostic indicator in neoadjuvantly treated adenocarcinoma of the esophagogastric junction
- (2018) Gerd Jomrich et al. Oncotarget
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy
- (2018) Mehmet A. Bilen et al. CANCER
- The Central Role of Inflammation Associated with Checkpoint Inhibitor Treatments
- (2018) Cristina Vajaitu et al. Journal of Immunology Research
- Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer
- (2017) Nicholas A. Taylor et al. JOURNAL OF CLINICAL INVESTIGATION
- Real world experience of immuno-oncology agents in metastatic renal cell carcinoma: Results from the IMDC.
- (2017) Steven Yip et al. JOURNAL OF CLINICAL ONCOLOGY
- Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
- (2016) Jonathan M. Pitt et al. IMMUNITY
- Prognostic significance of modified Glasgow Prognostic Score in patients with non-metastatic clear cell renal cell carcinoma
- (2016) Dae Sung Cho et al. Scandinavian Journal of Urology
- Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups
- (2016) G. de Velasco et al. Cancer Immunology Research
- Prognostic Role of C-Reactive Protein In Urological Cancers: A Meta-Analysis
- (2015) Liang Zhou et al. Scientific Reports
- Comparison of the prognostic value of longitudinal measurements of systemic inflammation in patients undergoing curative resection of colorectal cancer
- (2013) G J K Guthrie et al. BRITISH JOURNAL OF CANCER
- Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour–stroma interaction
- (2013) T Nagasaki et al. BRITISH JOURNAL OF CANCER
- Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
- (2013) Christiane Meyer et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- TNF signaling drives myeloid-derived suppressor cell accumulation
- (2012) Xueqiang Zhao et al. JOURNAL OF CLINICAL INVESTIGATION
- An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study
- (2011) M J Proctor et al. BRITISH JOURNAL OF CANCER
- Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group
- (2011) Judith Manola et al. CLINICAL CANCER RESEARCH
- Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature
- (2011) Digant Gupta et al. Nutrition Journal
- On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data
- (2011) Hajime Uno et al. STATISTICS IN MEDICINE
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
- (2009) Daniel Y.C. Heng et al. JOURNAL OF CLINICAL ONCOLOGY
- Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
- (2009) S. Ostrand-Rosenberg et al. JOURNAL OF IMMUNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started